KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to -$63.3 million.

  • West Pharmaceutical Services' Cash from Investing Activities rose 2289.89% to -$63.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$314.6 million, marking a year-over-year increase of 1779.46%. This contributed to the annual value of -$378.7 million for FY2024, which is 271.22% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported Cash from Investing Activities of -$63.3 million as of Q3 2025, which was up 2289.89% from -$75.2 million recorded in Q2 2025.
  • West Pharmaceutical Services' 5-year Cash from Investing Activities high stood at -$54.5 million for Q1 2021, and its period low was -$108.8 million during Q4 2023.
  • Over the past 5 years, West Pharmaceutical Services' median Cash from Investing Activities value was -$77.4 million (recorded in 2021), while the average stood at -$78.9 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 7084.64% in 2021, then soared by 2569.17% in 2025.
  • West Pharmaceutical Services' Cash from Investing Activities (Quarter) stood at -$77.4 million in 2021, then decreased by 22.48% to -$94.8 million in 2022, then decreased by 14.77% to -$108.8 million in 2023, then rose by 3.68% to -$104.8 million in 2024, then surged by 39.6% to -$63.3 million in 2025.
  • Its last three reported values are -$63.3 million in Q3 2025, -$75.2 million for Q2 2025, and -$71.3 million during Q1 2025.